文献速递中医内科中药与中成药合理使用

中药治疗特应性皮炎:八项高质量随机安慰剂对照试验的证据

Efficacy and safety of Chinese herbal medicine for atopic dermatitis: Evidence from eight high-quality randomized placebo-controlled trials.
PubMed 文献 · Front Pharmacol · 2022-09-27

本研究系统检索多个数据库,纳入8项中药与安慰剂对照的高质量随机对照试验,共662例特应性皮炎患者,采用Meta分析评估中药的疗效与安全性。结果显示中药组EASI-90应答率更高,SCORAD、BSA、皮损评分、VAS、睡眠评分及IGA均有改善,但DLQI/CDLQI和IgE水平两组无统计学差异,中药组不良事件发生率略高。

要点

  • 中药可改善特应性皮炎患者皮损面积与严重程度及睡眠质量。
  • 中药对生活质量(DLQI/CDLQI)和IgE水平未见显著改善。
  • 中药组不良事件发生率略高于安慰剂组,但总体安全性可接受。

核心结论

  • 中药可改善特应性皮炎患者皮损大小与严重程度及睡眠质量,对生活质量和IgE水平无显著改善。
  • 中药组不良事件发生率略高于安慰剂组,但比较两组不良事件后认为中药是安全的。

研究设计与样本

  • 系统检索PubMed、Embase、Cochrane Library、Web of Science、CNKI、VIP和万方数据库,纳入中药与安慰剂对照的高质量随机对照试验。
  • 共纳入662例患者,试验组322例,对照组340例,采用RevMan 5.3进行Meta分析,并用GRADE Profiler 3.6评价证据等级。

主要发现

  • EASI-90应答率中药组高于安慰剂组(RR,3.72;95% CI,1.76至7.83;p=0.01)。
  • SCORAD(RR,-10.20)、BSA(RR,-2.01)、表面损伤评分(RR,-2.25)、VAS(RR,-1.90)、睡眠评分(RR,-2.16)及IGA改善(RR,2.94)在中药组均改善。
  • DLQI或CDLQI改善两组无统计学差异(MD,-0.47;95% CI,-1.30至0.37;p=0.27)。
  • IgE水平两组无显著差异(MD,-62.76;95% CI,-809.58至684.05;p=0.87)。
  • 不良事件发生率中药组略高于安慰剂组(RR,1.42;95% CI,1.06至1.90;p=0.02)。

临床怎么用

  • 可考虑将中药用于改善特应性皮炎患者的皮损严重程度和睡眠质量。
  • 应告知患者中药对生活质量和IgE水平可能无显著改善。
  • 使用中药时需关注不良事件发生风险,监测安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The use of Chinese herbal medicine (CHM) for the treatment of atopic dermatitis (AD) has gained attention. This quantitative study systematically evaluated the efficacy and safety of CHM for the treatment of AD in eight high-level clinical trials, resulting in a high level of clinical evidence. Methods: Several databases were searched, including PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), the Chongqing VIP Chinese Science (VIP), and Wanfang Database. High-quality randomized controlled trials (RCTs) comparing CHM with placebo were included. The 95% confidence interval (CI) of the risk ratio (RR) was calculated using software (RevMan 5.3) and a meta-analysis was performed. Evidence level evaluation using GRADE Profiler 3.6. Results: In total, 662 patients (322 in the experimental group and 340 in the control group) were included. The response rate of the Eczema Area and Severity Index (EASI) -90 was higher in the CHM group than in the placebo group (RR, 3.72; 95% CI, 1.76 to7.83; p = 0.01). Furthermore, the scoring of atopic dermatitis (SCORAD) (RR, -10.20), body surface area (BSA) (RR, -2.01), surface damage score (RR, -2.25), visual analog scale (VAS) (RR, -1.90), and sleep score (RR, -2.16), improvement of investigator's global assessment (IGA) (RR, 2.94) improved in the CHM group. The results showed no statistical difference between CHM and placebo (MD, -0.47; 95% CI, -1.30, 0.37; p = 0.27) in improving the Dermatology Life Quality Index (DLQI) or children's DLQI (CDLQI). There was also no significant difference in the IgE level between the two groups (MD, -62.76; 95% CI, -809.58, 684.05; p = 0.87). However, the adverse events (AEs) rate was slightly higher in patients treated with CHM than in those treated with placebo (RR, 1.42; 95% CI, 1.06-1.90; p = 0.02). Conclusion: CHM improved the size and severity of the skin lesions and sleep quality in patients with AD. Comparing the adverse effects between the two groups, CHM is safe. However, CHM does not improve the quality of life or the patient's IgE levels.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Cai X, Sun X, Liu L, et al. Efficacy and safety of Chinese herbal medicine for atopic dermatitis: Evidence from eight high-quality randomized placebo-controlled trials. Front Pharmacol. 2022. PMID: 36238577. doi:10.3389/fphar.2022.927304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。